CNF combination as adjuvant treatment in breast cancer patients is well tolerated

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 376-378

  Hirvikoski, Pasi P ^a   Kumpulainen, Eero J ^a   Johansson, Risto T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adjuvant; Breast; Chemotherapy; Cyclophosphamide,; Fluorouracil; Mitoxantrone; Neoplasm; Side effects

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; MITOXANTRONE;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CONSTIPATION; DIARRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; RASH; STOMATITIS; VOMITING;

EID: 0031011246     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00010     Document Type: Article

References (12)

1. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy; 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339: 71-85.
2. Consensus conference. Adjuvant chemotherapy for breast cancer. J Am Med Ass 1985; 254: 3461-3.
3. Henderson IG. Adjuvant systemic therapy of early breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast Diseases, 2nd edn. Philadelphia: Lippincott 1992: 427-86.
4. Carpenter JT, Velez-Garcia E, Aron BS, et al. A Southeastern Cancer Study Group study. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer. Proc Am Soc Clin Oncol 1994; 13: A68.
5. Marty M, Bliss JM, Coombes RC, et al. Cyclophosphamide (C), methotrexate (M), fluorouracil (F) (CMF) versus F-epirubicin (E)-C (FEC) chemotherapy in premenopausal women with node positive breast cancer: Results of a randomized trial. Proc Am Soc Clin Oncol. 1994; 13: A50.
6. Neidhart JA, Gochnour D, Roach R, Hoth R, Young D. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 1986; 4: 672-7.
7. Holmes FA, Yap H-Y, Esparza L, et al. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer 1987; 59: 1992-9.
8. Bennet JM, Muss HB, Doroshow JH, et al. A multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611-20.
9. Miller AB, Hoogstraten B, Staquet M, Winkler H. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
10. Isacson R, Safra T, Ben-Dor CG, Uziely, Brufman G. A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and S-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes. Anti-Cancer Drugs 1993; 4: 189-92.
11. Goldhirsch A, Gelber RD, Prince KN, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994; 343: 377-81.
12. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. NCI Monogr 1986; 1: 105-9.